Get the Daily Brief
Latest Biotech News
Lilly’s triple‑agonist retatrutide meets Phase III goals — diabetes and weight outcomes
Eli Lilly reported positive top‑line Phase III results for retatrutide, a GIP/GLP‑1/glucagon triple‑agonist, showing clinically meaningful reductions in A1C and large weight loss in adults with...
Novartis pays $2B up front for Synnovation PI3Kα programs — franchise defense
Novartis agreed to acquire Pikavation Therapeutics, a Synnovation subsidiary, for $2 billion up front to secure next‑generation pan‑mutant PI3Kα inhibitors including SNV‑4818. The deal could reach...
Muscle‑building hopes fade — Roche and Genentech halt candidates
Roche announced it will stop development of emugrobart after key studies failed to show consistent improvements in muscle growth and motor function. Separately, Genentech ended development of a...
FDA presses for sham‑surgery control in uniQure’s Huntington gene trial — regulator unmoved by external controls
The FDA has told uniQure that external‑control data from Phase I/II studies are insufficient and recommended a prospective, randomized, double‑blind, sham‑surgery‑controlled trial of AMT‑130, an...
Tumor whole‑genome sequencing shows real‑world clinical utility — Nature Medicine series
A Nature Medicine real‑world analysis of 888 patients demonstrated that routine paired tumor‑normal whole‑genome sequencing (WGS) succeeded in 89% of cases with a median 6‑working‑day turnaround...
Abbott to close Exact Sciences buy — $23B deal seals diagnostics push
Abbott announced the completion of its $23 billion acquisition of Exact Sciences after securing regulatory clearances and shareholder approval. The move brings Cologuard, Oncotype DX and...
Nautilus Voyager lands Baylor access — single‑molecule proteomics readied for research use
Nautilus Biotechnology added Baylor College of Medicine as the first customer in its Voyager early access program, enabling Baylor investigators to test the platform’s single‑molecule proteomics...
In vivo CAR‑T edges closer — researchers reprogram T cells inside living hosts
Researchers reported methods to generate functional CAR‑T cells directly in vivo through targeted genetic engineering, demonstrating on‑target reprogramming of endogenous T cells without ex vivo...
Earendil Labs raises $787M — AI platform scales drug pipeline
Earendil Labs announced a $787 million private financing to expand an AI-driven drug discovery platform that the company says has produced more than 40 programs. The funding positions Earendil to...
Verily raises $300M: Alphabet loses majority control
Verily secured $300 million in outside capital that ends Alphabet’s controlling stake in the healthcare innovation company, the firm announced. The financing—led by Series X Capital with other...
Abbott closes $23B Exact Sciences buy — Diagnostics becomes core growth play
Abbott announced completion of its $23 billion acquisition of Exact Sciences after regulatory clearances, folding Cologuard, Oncotype DX and other cancer‑screening assays into Abbott’s diagnostics...
Novartis pays $2B upfront — Next‑gen PI3Kα joins breast cancer arsenal
Novartis agreed to pay $2 billion upfront to acquire an experimental, pan‑mutant‑selective PI3Kα inhibitor from Synnovation Therapeutics, aiming to bolster or defend its breast‑cancer franchise....
Roche and Genentech abandon muscle‑building programs — Trials fail to show benefit
Roche confirmed it is halting development of emugrobart after a key study failed to show consistent improvements in muscle growth and motor function, notifying European patient communities....
Lilly’s triple‑agonist retatrutide clears Phase III A1C and weight endpoints
Eli Lilly reported positive top‑line Phase III results for retatrutide, a GIP/GLP‑1/glucagon ‘triple’ agonist, showing significant A1C reductions and substantial weight loss in people with type 2...
FDA clears high‑dose Wegovy fast — Commissioner’s voucher accelerates review
The FDA approved a 7.2 mg high‑dose formulation of Novo Nordisk’s Wegovy under a commissioner’s voucher program that compressed review to roughly two months. Novo said the higher‑dose injectable...
FDA and NIH push to pare animal testing — Draft guidance issued
The FDA and NIH published draft guidance and policy moves aimed at validating non‑animal 'new approach methodologies' (NAMs) for toxicology and early safety studies, signaling a regulatory shift...
In vivo CAR‑T edges closer — Precision engineering generates CAR T inside patients
Two independent research teams reported advances toward generating CAR‑T cells in vivo, demonstrating programmable, site‑specific integration or dual‑vector approaches that reprogram T cells...
Pelareorep wins FDA fast track — Oncolytic virus targets KRAS‑mutant colorectal cancer
Oncolytics Biotech said the FDA granted Fast Track designation to pelareorep (Reolysin) in combination with bevacizumab and FOLFIRI for second‑line treatment of KRAS‑mutant, microsatellite‑stable...
Abbott to close $23 billion Exact Sciences deal Monday – Enters cancer‑screening market
Abbott announced the scheduled close of its $23 billion acquisition of Exact Sciences after receiving final regulatory clearances. The deal brings Cologuard, Oncotype DX, Oncodetect and...
Novartis pays $2B upfront for next‑gen PI3Kα – Rivalry around breast‑cancer franchise intensifies
Novartis agreed to a deal that pays Synnovation roughly $2 billion upfront for a pan‑mutant‑selective PI3Kα inhibitor aimed at breast cancer. The acquisition targets a next‑generation molecule...